OC
CLYM

Oppenheimer & Co’s Climb Bio CLYM Stock Holding History

Oppenheimer & Co’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$541K Buy
+41,498
New +$429K 0.01% 1219

Other funds holding CLYM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Oppenheimer & Co's CLYM Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in Climb Bio (CLYM) in Q2 2026: 41,498 shares worth $541K. The stake represents 0.01% of the portfolio and ranks #1219 among its holdings.

22 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Oppenheimer & Co held 41,498 shares of Climb Bio worth $541K as of Q2 2026.
  • Climb Bio was a new Oppenheimer & Co position in Q2 2026.
  • Climb Bio made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1219 holding.
  • 22 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.